Physician profile
Daniel W Gillette
NPI 1053376475
$47,919.02
in general payments reported to CMS, 2019-2025
30 companies · $44K in 2025
The $44K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $564 · 2021: $759 · 2022: $510 · 2023: $708 · 2024: $999 · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $40K · Food and Beverage: $3,076 · Travel and Lodging: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $40,350.00 |
| Food and Beverage | $3,076.02 |
| Travel and Lodging | $2,396.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30,391.14 | 2021-2025 | Qelbree, Qelbree |
| Mdd US Operations, LLC | $13,797.10 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $504.45 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $448.49 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $408.71 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $403.82 | 2020-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $351.30 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.73 | 2020-2025 | Caplyta |
| Alkermes, INC. | $294.51 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $207.25 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $103.82 | 2020-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $85.04 | 2020-2023 | Jornay Pm |
| Corium, LLC | $66.99 | 2023-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $63.94 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.44 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $35.38 | 2019-2021 | |
| Allergan, INC. | $31.90 | 2020 | |
| Neos Therapeutics, LP | $30.61 | 2020 | |
| Vertical Pharmaceuticals, LLC | $29.90 | 2019-2020 | |
| Eisai INC. | $29.01 | 2020-2021 | |
| Axsome Therapeutics, INC. | $25.35 | 2024 | Auvelity |
| Bioxcel Therapeutics, INC. | $22.89 | 2024 | Igalmi |
| Shire North American Group INC | $20.14 | 2019 | |
| Almatica Pharma LLC | $15.95 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.91 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $15.08 | 2025 | Jornay Pm |
| Tris Pharma INC | $14.03 | 2020 | |
| Indivior INC. | $13.77 | 2021 | |
| Adlon Therapeutics L.P. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.